No black box warning on record for Ctexli

As of the latest FDA labeling reviewed, Ctexli (CHENODIOL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Ctexli medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Obtain baseline liver transaminase and total bilirubin levels in all patients and monitor yearly and as clinically indicated. Interrupt treatment until the levels have returned to baseline values. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI. ( 5.1 ) 5.1 Hepatotoxicity Chenodiol, including CTEXLI, has been associate

No black box warning on record for Ctexli

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Obtain baseline liver transaminase and total bilirubin levels in all patients and monitor yearly and as clinically indicated. Interrupt treatment until the levels have returned to baseline values. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI. ( 5.1 ) 5.1 Hepatotoxicity Chenodiol, including CTEXLI, has been associate

Ctexli Black Box Warning

No black box warning on record for Ctexli

Other warnings & precautions

Ctexli Black Box Warning

No black box warning on record for Ctexli

Other warnings & precautions